Boosted tipranavir versus darunavir in treatment-experienced patients: Observational data from the randomized POTENT trial

Drugs in R and D

Volumn 11, Issue 4, 2011, Pages 295-302

  Elgadi, Mabrouk M ^a   Piliero, Peter J ^b  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; RITONAVIR PLUS TIPRANAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; OPTIMIZED BACKGROUND REGIMEN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; PYRONES; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 82655189302     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11596340-000000000-00000     Document Type: Article

References (14)

1. Luna B, Townsend MU. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther 2007; 29 (11): 2309-18 (Pubitemid 350298126)
2. Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14 (13): 1943-8
3. Croom KF, Keam SJ. Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 2005; 65 (12): 1669-77 (Pubitemid 41138987)
4. Tipranavir: PNU 140690, tipranavir. Drugs R D 2006; 7 (1): 55-62
5. Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008; 47 (4): 429-40 (Pubitemid 351372104)
6. Coffey S. Darunavir (Prezista).HIVInSite.December 17 2010; University of California, San Francisco [online]. Available from URL: http://hivinsite.ucsf. edu/InSite?page=ar-03-10 [Accessed 2011 Jun 13]
7. Willig JH, Aban I, Nevin CR, et al. Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for threeclass experienced patients at 48 weeks. AIDS Res Hum Retroviruses 2010; 26 (12): 1279-85
8. Curran A, Gutierrez M, Deig E, et al. Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother 2010; 65 (10): 2195-203
9. de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24 (3): 379-88 (Pubitemid 351457745)
10. De Luca A. Resistance to newly approved and investigational protease inhibitors. Curr Opin HIV AIDS 2007; 2 (2): 130-6 (Pubitemid 46941131)
11. Fox MP, Ive P, Long L, et al. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53 (4): 500-6
12. Weinberg A, Dickover R, Britto P, et al. Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS 2008; 22 (17): 2267-77
13. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359 (4): 355-65
14. Gatell JM, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr 2010; 53 (4): 456-63